Hostname: page-component-cd9895bd7-gbm5v Total loading time: 0 Render date: 2024-12-25T05:56:40.159Z Has data issue: false hasContentIssue false
  • English
  • Français

Outcomes Measurement: The Key to the Appropriate Use of Pharmaceuticals

Published online by Cambridge University Press:  10 March 2009

Rondi R. Grey ,
Raymond J. Townsend  and
Charles A. Sanders
Rondi R. Grey
Affiliation:
Biochem Pharma, Inc.
Raymond J. Townsend
Affiliation:
Glaxo Wellcome, Inc.
Charles A. Sanders
Affiliation:
Glaxo Wellcome, Inc.
Get access Rights & Permissions [Opens in a new window]

Abstract

Outcomes measurement will be key to the appropriate use of Pharmaceuticals as health care costs continue to rise. The generation of data showing the clinical, economic, and humanistic outcomes of pharmaceutical care will be essential to avoid decision making based solely on cost and to ensure that cost-effective, high-quality health care remains the health care system's top priority.

Type
Special Section: The Rational Use of Therapeutic Drugs
Information
International Journal of Technology Assessment in Health Care , Volume 11 , Issue 3 , Summer 1995 , pp. 472 - 484
Copyright
Copyright © Cambridge University Press 1995

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Australian Government Publishing Service. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee. Canberra: Australian Government Publishing Service, 08 1992.Google Scholar
2.Bootman, J. L., Townsend, R. J., & McGhan, W. F.Principles of pharmacoeconomics. Cincinnati, OH: Harvey Whitney Books Company, 1991.Google Scholar
3. Canada. Guidelines for economic evaluation of Pharmaceuticals. 06 27, 1994, draft 1.4.Google Scholar
4.Carpenter, C. E., Weitzel, L. C., Johnson, N. E., & Nash, D. B. Cost accounting supports clinical evaluations. Healthcare Financial Management. 04 1994, 40–43.Google Scholar
5.Cassak, D.Outcomes studies and the new information brokers. In Vivo, 1993, 11, 29.Google Scholar
6.Congressional Budget Office, U.S. Congress. Managed competition and its potential to reduce spending. Washington DC: U.S. Government Printing Office, 1993, 2.Google Scholar
7.Foundation for Health Services Research. Health outcomes research: A primer. Washington, DC: Foundation for Health Services Research, 1992, 8.Google Scholar
8.Hongfield, G., & Patin, J.A two-year clinical and economic follow-up of patients on clozapine. Hospital and Community Psychiatry, 1990, 41, 882–85.Google Scholar
9.Juran, J. M.Juran on quality by design. New York: The Free Press, 1992.Google Scholar
10.Kozma, C. M., Reeder, C. E., & Schulz, R. M.Economic, clinical, and humanistic outcomes: A planning model for pharmacoeconomic research. Clinical Therapeutics, 1993, 5, 1127.Google Scholar
11.National Coalition for Quality Assurance. Health plan employer data and information set and users' manual, Version 2.0. Washington, DC: National Coalition for Quality Assurance, 1993.Google Scholar
12.Osterhaus, J. T., Townsend, R. J., Gandek, B., & Ware, J. E.Measuring the functional status and well-being of patients with migraine headaches. Headache, 1994, 34, 337–43.CrossRefGoogle Scholar
13.Piercey, L.Biotech execs court Kennedy. Bio World Today, 04 26, 1994, 5, 1.Google Scholar
14.Ross, R. N., Morris, M., Sakowitz, S. R., & Berman, B. A.Cost-effectiveness of including cromolin sodium in the treatment program for asthma: A retrospective record-based study. Clinical Therapeutics, 1988, 10, 2, 188–203.Google ScholarPubMed
15.Soumerai, S. B., McLaughlin, T. J., Ross-Dronan, D., et al. Effects of limiting drug reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. New England Journal of Medicine, 1994, 331, 650–55.CrossRefGoogle ScholarPubMed
16.Townsend, R. J.Post-marketing drug research and development. Drug Intelligence Clinical Pharmacy 1987, 21, 134–36.CrossRefGoogle Scholar
17. 42 USC Section 299(b) (West Supp. 1993).Google Scholar
18.Zitter Group. The 1992 Insurance Outcomes Study. Final Report. 03 1993, 21.Google Scholar